Casey Bonaquist, DO
Obesity Medicine · Jacksonville, FLNPI 1689836918
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Novo Nordisk at 27.5% of the total. Reporting peaked in 2024 at $770 and has fallen 97.9% since, to $16 in 2025.
Across 81 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$397
- GSK$155
- Lilly USA, LLC$111
- Amgen$110
- Boehringer Ingelheim$107
- Pfizer$60
- plus $503 from 16 others
What the payments were for
- Food & beverage$1,443100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $397 |
| GSK | 7 | $155 |
| Lilly USA, LLC | 6 | $111 |
| Amgen | 7 | $110 |
| Boehringer Ingelheim | 5 | $107 |
| Pfizer | 3 | $60 |
| AbbVie | 3 | $60 |
| Exact Sciences | 3 | $56 |
| Merck | 3 | $53 |
| Johnson & Johnson | 2 | $41 |
| Dynavax Technologies Corporation | 2 | $39 |
| Hologic Sales And Service, LLC | 2 | $35 |
| Vivus LLC | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Tris Pharma Inc | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $16 |
How this compares
$1,443 in reported general payments places this provider in the 80th percentile of 21 obesity medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 72 | $75,638 |
| OzempicSemaglutide | 64 | $71,612 |
| EliquisApixaban | 36 | $46,411 |
| RybelsusSemaglutide | 23 | $40,532 |
| ProliaDenosumab | 14 | $23,861 |
| JanuviaSitagliptin Phosphate | 19 | $22,742 |
| XareltoRivaroxaban | 11 | $17,480 |
| SynthroidLevothyroxine Sodium | 68 | $4,273 |
| Atorvastatin Calcium | 266 | $2,871 |
| Bupropion XlBupropion Hcl | 42 | $2,425 |
| Duloxetine Hcl | 48 | $1,911 |
| Levothyroxine Sodium | 242 | $1,879 |
| Omeprazole | 146 | $1,716 |
| Losartan Potassium | 157 | $1,693 |
| Gabapentin | 92 | $1,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $397 | $112,14487 claims |
| Lilly USA, LLCMounjaro | $111 | $75,63872 claims |
| PfizerEliquis | $60 | $46,41136 claims |
| AmgenProlia | $110 | $23,86114 claims |
| MerckJanuvia | $53 | $22,74219 claims |
| Johnson & JohnsonXarelto | $41 | $17,48011 claims |
| AbbVieSynthroid | $60 | $4,27368 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 21 obesity medicine providers in Florida.
Other obesity medicine in Jacksonville
- Scott LynchJacksonville$90
- Lisa FerreiraWesley Chapel$183K
- Jawan Ayer ColeTampa$85K
- Bharti ShetyeTampa$21K
- Dauris FiguerasWeston$7K
- Celine GisbertPensacola$1K
- Grettel Rodriguez GarciaVero Beach$553
- Kelley LangTallahassee$362
- Marci MannaPunta Gorda$353
- Lindsay WilesTampa$327
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.